



BRINGING CIVIL SOCIETY TOGETHER
TO END THE TUBERCULOSIS EPIDEMIC

WWW.TBCOALITION.EU

[@TBCOALITION](https://twitter.com/TBCOALITION) [f/TBEUROPECOALITION](https://facebook.com/TBEUROPECOALITION)

TB EUROPE COALITION ANNUAL ACCOUNTS 2025

TABLE OF CONTENTS

REPORT OF THE BOARD3

FINANCIAL STATEMENTS6

 Balance Sheet as per 31 December 2025.....6

 Profit and Loss Account 2025.....7

 Generally accepted accounting principles for valuation and determination of results.....8

 Notes to the Balance sheet as per 31 December 20259

 Notes to the Statement of income and expenditures 2025.....11

REPORT OF THE BOARD

Stichting TB Europe Coalition (hereinafter – TBEC or the Foundation) is registered at the Dutch Chamber of Commerce in Amsterdam with registration number 858222565.

The members of the TBEC Board are pleased to present the Foundation’s 2025 financial statement.

Vision, Mission and Core Values

TBEC **vision**: a world free of TB.

TBEC **mission**: civil society driving the TB response.

Core Values:

- **Human Rights and Gender-Balanced Approach:** Prioritizing dignity, autonomy, and rights of TB-affected individuals, ensuring equitable access to quality healthcare free from stigma and discrimination, with a focus on children and adolescents.
- **Social Justice:** Addressing social and economic determinants of TB, such as poverty, stigma, and discrimination, through people-centered care to tackle health inequalities.
- **Empowerment:** Enabling civil society and TB-affected communities to meaningfully participate in the TB response, promoting comprehensive and inclusive healthcare solutions.
- **Accountability:** Promoting multisectoral collaboration under National TB Programmes and WHO’s Multisectoral Accountability Framework (MAF-TB) to ensure accountability across health sectors.
- **Independence and Transparency:** Accepting funding only from donors aligned with TBEC’s vision, maintaining transparency in resource allocation, and challenging oppression caused by power inequalities.

Objectives:

- **Building Capacity of Civil Society and Communities:** Enhance civil society’s capacity for TB prevention, diagnosis, and care, including knowledge of new TB technologies and co-creating people-centered services.
- **Maintain TBEC Leadership in Communities, Rights and Gender (CRG) Advocacy:**
 - Lead CRG advocacy efforts.
 - Expand the Standardized Package of Community-Based Support Services to five additional countries.
 - Advocate for access to new TB drugs and diagnostics via engagement with national TB Caucuses.
 - Promote social protection and Universal Health Coverage in Eastern Europe and Central Asia.
- **TBEC’s Institutional Development Through Research and Innovation:**
 - Develop a social science research agenda to explore TB-related social issues and behavioral patterns.
 - Support innovation in TB care and prevention through community-engaged research.

- **TBEC Partnership and Strategic Geographical Expansion:**
 - Build partnerships with EU health organizations to influence TB policies in low-burden and EECA countries.
 - Transfer best practices to/from EECA by engaging patient organizations.
- **Achieving Financial Stability:**
 - Seek project funding from diverse donors.
 - Pursue unrestricted funding from private individuals, institutions, and crowdfunding platforms.

The Foundation makes every effort inter alia to attain and accomplish its objective by:

- being a regional civil society network bringing together both individuals and organisations from across the region in order to strengthen the role of civil society within the regional response to tuberculosis, health and well - being, and to increase the political and financial commitment required to effectively manage both the tuberculosis epidemic, and increase the health and well-being of all persons; and
- collaborating with medical, governmental, private, and civil society bodies of all types.

The Foundation does not have the objective to make profits.

Projects

In 2025, TBEC implemented the following main projects and funding arrangements:

- 1) as grantee under the UNITAID - “Community-Driven Approaches for Transformative Change to Combat DR-TB (Combat DR-TB)”;
- 2) as grantee under the Stop TB Partnership/UNOPS - “Challenge Facility for Civil Society” Round 12;
- 3) as grantee under the Global Fund, Switzerland (CRG Project, 2024 – 2026), Long term capacity strengthening of TB community networks and organizations;
- 4) as grantee under TAG ASCENT DR-TB CATALYTIC small grants;
- 5) as service provider under the WHO Agreement for Performance of Work for MAF-TB webinars and related deliverables;
- 6) as administrator of reimbursement/pass-through funds from EFA for TBEC members participating in the European Respiratory Patient Academy in Prague;
- 7) as implementer/administrator of Paris seminar implementation funding received from DRFIP Île-de-France et de Paris.

Board Members

As of 31 December 2025, TBEC Board consisted of 13 members:

- | | |
|------------------------------|----------------------|
| • Mr. Paul John Sommerfeld | Chair |
| • Ms. Yuliya Chorna | Co-Chair |
| • Dr. Jonathan Joseph Stillo | Vice-Chair |
| • Mr. Stefan Radut | Vice-Chair/Treasurer |
| • Ms. Mona Drage | Board Member |
| • Ms. Kira Grozava | Board Member |
| • Ms. Cristina Enache | Board Member |
| • Mr. Denis Godlevskiy | Board Member |
| • Mr. Daniel Kashnitsky | Board Member |
| • Ms. Cristina Celan | Board Member |
| • Ms. Oleksandra Denysenko | Board Member |
| • Ms. Oxana Rucşineanu | Board Member |
| • Mr. Bakyt Myrzaliev | Board Member |

The members of the Board do not receive any reward for their endeavour and contribution to the TB Europe Coalition.

FINANCIAL STATEMENTS

Balance Sheet as per 31 December 2025

(EUR)

ASSETS	Notes	31/12/2025	31/12/2024
Current assets		91.620,00	122.399,00
<i>Receivables</i>		0	0
Deferred income		0	0
<i>Cash and cash equivalents</i>	1	91.620,00	122.399,00
		91.620,00	122.399,00

LIABILITIES	Notes	31/12/2025	31/12/2024
Financing		91.620,00	122.399,00
Restricted Financing	2	28.922,00	61.063,00
Unrestricted Financing	3	62.698,00	61.336,00
Payables		0	0
Accrued expenses		0	0
		91.620,00	122.399,00
		91.620,00	122.399,00

TBEC, as a non-profit organisation, does not recognize commitments for future contracts or expenses until official confirmation of funding has been received from donors. Agreements for the provision of goods or services may only be signed after donor reports have been reviewed and subsequent tranches approved. This explains the absence of receivables and payables as of the balance sheet date.

Profit and Loss Account 2025

(EUR)

INCOME	Notes	2025	2024
Income from own fundraising		406.324,00	368.274,00
Grants, service contract income and reimbursement/pass-through funds from international organisations	4	406.324,00	368.274,00
Grants from businesses			
Other: Donations			
Other income:		1.231,00	66.036,00
Unrestricted income	A	1.231,00	66.036,00
		407.555,00	434.310,00
EXPENDITURES	Notes	2025	2024
Implementation of projects activities	B	438.334,00	437.124,00
		438.334,00	437.124,00
SURPLUS/(DEFICIT)		(-30.779,00)	(-2.814,00)

Note A: Other income / Unrestricted income in 2025 represents miscellaneous unrestricted income not subject to donor restrictions. Residual unrestricted amounts arising from implementation funding, reimbursement/pass-through arrangements and overhead or partner support cost balances are reflected within unrestricted financing once they are no longer subject to donor restrictions.

Note B: Expenditures in 2025 relate to the implementation of TBEC's donor-funded projects and organisational activities and include project costs, partner/sub-grant disbursements, consultancy and service provider fees, travel and event-related costs, bank charges and other eligible operational expenses. The deficit for the year reflects the use of funds received in previous reporting periods for the implementation of activities in 2025.

Generally accepted accounting principles for valuation and determination of results

Accounting policies

The financial statements have been prepared in accordance with accounting principles generally accepted in the Netherlands. The financial year coincides with the calendar year. The financial statements are presented in euros and rounded to the nearest euro.

Income from grants, project funding, service contracts and reimbursement arrangements is recognised when the related funds are received. Funds received for a specific purpose and not yet spent at year-end are presented as restricted financing.

Funds received for onward disbursement to participants or partners are recognised together with the corresponding expenditure when TBEC is responsible for administering and reporting on such funds. Any residual unrestricted amount is recognised as unrestricted income or unrestricted financing, as applicable.

Expenditures are recognised when payments are made and are supported by relevant documentation. Returned or failed payments are not recognised as income. Where a payment is returned and subsequently re-issued, only the final effective payment is reflected as expenditure, while related bank charges are recognised as expenditure.

Foreign currency transactions are converted into euros using the official European Central Bank exchange rate on the transaction date. Foreign currency balances at year-end are translated using the European Central Bank exchange rate at the balance sheet date.

All assets and liabilities are recorded at nominal value.

Notes to the Balance sheet as per 31 December 2025

1. *Cash and cash equivalents:*

Bank account	Balance sheet (EUR)	Bank account (Account currency)
ABN AMRO main account balance / unrestricted funds	55.798,00	EUR 55.797,94
ABN AMRO foreign account balance (Stop TB Project, TAG Project)	6.899,00	USD 8.106,56
ABN AMRO foreign currency account balance (Unitaid Project)	11.410,00	USD 13.406,99
ABN AMRO foreign account balance (CRG Project, GF TA Projects)	17.512,00	USD 20.577,00
TOTAL	91.620,00	

Balances presented in euros are rounded to the nearest euro. Balances denominated in US dollars are translated into euros using the European Central Bank exchange rate at the balance sheet date, 31 December 2025.

TBEC does not use petty cash and does not have any deposits.

2. *Restricted funding*

Bank account	Balance sheet (EUR)	Bank account (Account currency)
Unitaid Project (Combat DR-TB)	11.410,00	USD 13.406,99
The Global Fund, Switzerland (CRG Project, GF TA Projects)	17.512,00	USD 20.577,00
TOTAL	28.922,00	

Balances at the balance sheet date 31 December 2025. The same conversion rule applies as in Note 1 above.

3. *Unrestricted funding*

Bank account	Balance sheet (EUR)	Bank account (Account currency)
ABN AMRO main account balance / unrestricted funds	55.798,00	EUR 55.797,94
Unrestricted / earned overhead and residual funds held on foreign currency account	6.900,00	USD 8.106,56
TOTAL	62.698,00	

The unrestricted financing balance includes unrestricted overhead / earned funds and residual amounts from implementation funding and reimbursement/pass-through arrangements after related costs, participant payments and bank fees have been covered. Differences of EUR 1 may arise due to rounding of foreign currency balances to the nearest euro.

Notes to the Statement of income and expenditures 2025

4. Grants, service contract income and reimbursement/pass-through funds from international organisations













Source of funding	Profit and loss account (EUR)	Disbursement amount (Disbursement currency)
STOP TB Partnership/UNOPS STOP TB Project, Round 12		
3 rd disbursement	63.990,00	USD 66.788,00
Sub-total	63.990,00	USD 66.788,00
The Global Fund, Switzerland (CRG Project, 2024 – 2026)		
2 nd disbursement	101.378,00	USD 112.499,00
Sub-total	101.378,00	USD 112.499,00
Unitaid Project (Combat DR-TB)		
1 st disbursement	96.888,00	USD 112.874,00
2 nd disbursement	96.014,00	USD 112.874,00
Sub-total	192.902,00	USD 225.748,00
TAG ASCENT DR-TB CATALYTIC small grants		
2 nd disbursement	8.803,00	USD 10.000,00
3 rd disbursement	4.323,00	USD 5.000,00
Sub-total	13.126,00	USD 15.000,00
World Health Organization - Agreement for Performance of Work / MAF-TB webinars		
1 st disbursement	3.460,00	USD 3.997,50
2 nd disbursement	3.395,00	USD 3.997,50
Sub-total	6.855,00	USD 7.995,00
DRFIP Île-de-France et de Paris / Paris seminar implementation funding		
1 st disbursement	17.459,00	EUR 17.459,00
2 nd disbursement	2.027,00	EUR 2.027,00
3 rd disbursement	6.002,00	EUR 6.002,00
Sub-total	25.488,00	EUR 25.488,00
EFA — European Respiratory Patient Academy reimbursement/pass-through funds		
1 st disbursement	2.125,00	EUR 2.125,00
2 nd disbursement	460,00	EUR 460,00
Sub-total	2.585,00	EUR 2.585,00
GRAND TOTAL	406.324,00	

Currency exchange policy. All foreign currency transactions are converted into euros using the official European Central Bank (ECB) exchange rate applicable on the transaction date. Official ECB exchange rate printouts are retained for each relevant transaction and are available upon request. Year-end balances in USD are translated into euros using the ECB exchange rate as of 31 December 2025.

5. *Surplus/(Deficit)*

The Statement of Income and Expenditures for 2025 reflects a deficit of **EUR 30.779**. This does not indicate a cash shortage. The deficit mainly results from the use of funds received in previous reporting periods for the implementation of activities in 2025. The total cash balance as of 31 December 2025 remains positive and amounts to **EUR 91.620** (see Note 1 to the Balance Sheet).

Signed by the TBEC Board members:

Mr. Paul John Sommerfeld	Chair	Signed by:  Signed by: 9886B2A64A496... (signature)
Ms. Yuliya Chorna	Co-Chair	 Signed by: D39D64DD08A40B... (signature)
Dr. Jonathan Joseph Stillo	Vice-Chair	 Signed by: C6AD96B976D44E6... (signature)
Mr. Stefan Radut	Vice-Chair/Treasurer	 Signed by: 31E8F912DBB3492... (signature)
Ms. Mona Drage	Board Member	 Signed by: 86AED0302F4426... (signature)
Ms. Kira Grozava	Board Member	 Signed by: 86AED0302F4426... (signature)
Ms. Cristina Enache	Board Member	 Signed by: 86AED0302F4426... (signature)
Mr. Denis Godlevskiy	Board Member	 Signed by: 9DD0E717445224DD... (signature)
Mr. Daniel Kashnitsky	Board Member	 Signed by: 86AED0302F4426... (signature)
Ms. Cristina Celan	Board Member	 Signed by: 86AED0302F4426... (signature)
Ms. Oleksandra Denysenko	Board Member	 Signed by: 86AED0302F4426... (signature)
Ms. Oxana Rucşineanu	Board Member	 Signed by: 86AED0302F4426... (signature)
Mr. Bakyt Myrzaliev	Board Member	 Signed by: 51E4813CCA3F466... (signature)